

ARDELYX, INC.  
Form 8-K  
May 19, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 19, 2015**

**ARDELYX, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**001-36485**  
**(Commission**

**File Number)**  
**34175 Ardenwood Blvd.**

**26-1303944**  
**(IRS Employer**

**Identification Number)**

**Fremont, CA 94555**

**(Address of principal executive offices, including Zip Code)**

**Registrant's telephone number, including area code: (510) 745-1700**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

On May 19, 2015, Ardelyx, Inc. (the Company ) announced that it will present clinical results from a Phase 2b trial evaluating tenapanor in patients with irritable bowel syndrome at the Digestive Disease Week (DDW) 2015 conference being held in Washington, D.C., from May 16-19, 2015. A copy of the press release is attached hereto as Exhibit 99.1, and a copy of the presentation of the data is attached hereto as Exhibit 99.2.

The information furnished under this Item 7.01 shall not be considered filed under the Securities Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information shall be considered filed or incorporated by reference therein.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits.**

Exhibit

No.	Description
99.1	Press Release dated May 19, 2015
99.2	Corporate Presentation of Ardelyx, Inc.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 19, 2015

ARDELYX, INC.

By: /s/ Mark Kaufmann  
Mark Kaufmann  
Chief Financial Officer

**EXHIBIT INDEX**

Exhibit

No.	Description
99.1	Press Release dated May 19, 2015
99.2	Corporate Presentation of Ardelyx, Inc.